Litigation Details for AstraZeneca LP v. InvaGen Pharmaceuticals Inc. (E.D.N.Y 2015)
✉ Email this page to a colleague
AstraZeneca LP v. InvaGen Pharmaceuticals Inc. (E.D.N.Y 2015)
| Docket | ⤷ Try a Trial | Date Filed | 2015-11-01 |
| Court | District Court, E.D. New York | Date Terminated | 2015-12-17 |
| Cause | 35:145 Patent Infringement | Assigned To | Kiyo A. Matsumoto |
| Jury Demand | None | Referred To | Gary R. Brown |
| Patents | 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca LP v. InvaGen Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for AstraZeneca LP v. InvaGen Pharmaceuticals Inc. (E.D.N.Y 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-11-01 | 1 | AstraZeneca’s U.S. Patent Nos. 6,251,910 (“the ’910 patent”), 6,525,060 (“the ’060 patent”), 7,250,419 (… (“the ’419 patent”), 7,265,124 (“the ’124 patent”), and 8,425,934 (“the ’934 patent”) ME1 21411463v… This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 19. On June 26, 2001, the U.S. Patent and Trademark Office…copy of the ’910 patent is attached hereto as Exhibit A. The claims of the ’910 patent are valid and enforceable | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
